Mountain Valley MD Holdings Inc.

OTCPK:MVMD.F Stock Report

Market Cap: US$7.6m

Mountain Valley MD Holdings Valuation

Is MVMD.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MVMD.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MVMD.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MVMD.F's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MVMD.F?

Key metric: As MVMD.F barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MVMD.F. This is calculated by dividing MVMD.F's market cap by their current book value.
What is MVMD.F's PB Ratio?
PB Ratio1.1x
BookCA$9.24m
Market CapCA$10.57m

Price to Book Ratio vs Peers

How does MVMD.F's PB Ratio compare to its peers?

The above table shows the PB ratio for MVMD.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.5x
BFRI Biofrontera
0.9x72.2%US$4.8m
MSTH Mystic Holdings
0.3xn/aUS$5.8m
CMND Clearmind Medicine
1.6xn/aUS$5.4m
NBY NovaBay Pharmaceuticals
3.1x81.3%US$3.3m
MVMD.F Mountain Valley MD Holdings
1.1xn/aUS$10.6m

Price-To-Book vs Peers: MVMD.F is good value based on its Price-To-Book Ratio (1.1x) compared to the peer average (1.5x).


Price to Book Ratio vs Industry

How does MVMD.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

22 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.69m
UPC Universe Pharmaceuticals
0.1xn/aUS$3.04m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.44m
MVMD.F 1.1xIndustry Avg. 1.8xNo. of Companies22PB012345+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: MVMD.F is good value based on its Price-To-Book Ratio (1.1x) compared to the US Pharmaceuticals industry average (1.7x).


Price to Book Ratio vs Fair Ratio

What is MVMD.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MVMD.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MVMD.F's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies